Treatment After Palbociclib-containing Regimens
NCT04517318 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2021-08-03
Summary
To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Professor · Fudan University
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-15
- Primary Completion
- 2021-04-15
- Completion
- 2021-07-15
Countries
- China
Study Locations
More Related Trials
-
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
NCT04289974 ·Status: UNKNOWN
-
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
NCT04394247 ·Status: COMPLETED
-
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
NCT04524728 ·Status: COMPLETED
-
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
NCT04498481 ·Status: COMPLETED
-
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
NCT02499146 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783 ·Status: RECRUITING ·Phase: PHASE1
-
Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC
NCT05343117 ·Status: UNKNOWN
-
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
NCT04318223 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients
NCT03541863 ·Status: COMPLETED
-
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
NCT07002177 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Eribulin in mTNBC Patients
NCT04541420 ·Status: COMPLETED
-
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
NCT05969184 ·Status: UNKNOWN ·Phase: PHASE2
-
Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
NCT04780347 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
NCT04460911 ·Status: COMPLETED
-
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
NCT05155566 ·Status: COMPLETED
-
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
NCT07117630 ·Status: RECRUITING ·Phase: PHASE2
-
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
NCT04526028 ·Status: UNKNOWN
-
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
NCT02536742 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
NCT04681287 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
NCT04671615 ·Status: COMPLETED
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
NCT04778982 ·Status: TERMINATED
-
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
NCT07071337 ·Status: RECRUITING ·Phase: PHASE3